Mirzaten (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, which increases the release of norepinephrine and serotonin. It also antagonizes 5‑HT2, 5‑HT3 and histamine H1 receptors, enhancing serotonergic activity while producing sedative effects that can improve sleep.

The appropriate dose of Mirzaten is determined by the prescribing clinician based on the individual’s medical condition, response to therapy, and tolerability. Patients should follow the dosage instructions provided by their healthcare professional.

Safety data for mirtazapine in pregnancy and lactation are limited. The prescriber must weigh potential benefits against possible risks to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss treatment options with their doctor.

To request Mirzaten, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with selective serotonin reuptake inhibitors (SSRIs), mirtazapine has a distinct receptor profile that often results in stronger sedative and appetite‑stimulating effects. This can be advantageous for patients with insomnia or weight loss, but may be less suitable for those who wish to avoid sedation.

Mirzaten should be stored at ambient temperature, below 25 °C, in its original packaging. Keep the product away from moisture, heat and direct sunlight to maintain stability and potency.

Mirzaten is taken orally, usually once daily in the evening to take advantage of its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include agranulocytosis or severe neutropenia, hepatic dysfunction, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, and the emergence or worsening of suicidal thoughts, particularly during the initial weeks of therapy.

Mirzaten is contraindicated in patients with known hypersensitivity to mirtazapine or any of its excipients. It should also be avoided in individuals currently taking monoamine oxidase inhibitors (MAOIs) or those with uncontrolled severe hepatic impairment.